Proteomic Characterization of High-Density Lipoprotein Particles from Non-Diabetic Hemodialysis Patients

被引:12
作者
Florens, Nans [1 ,2 ]
Calzada, Catherine [1 ]
Delolme, Frederic [3 ]
Page, Adeline [3 ]
Guebre Egziabher, Fitsum [1 ,2 ]
Juillard, Laurent [1 ,2 ]
Soulage, Christophe O. [1 ]
机构
[1] Univ Claude Bernard Lyon 1, Univ Lyon, INSA Lyon, CarMeN,INSERM,U1060,U1397,INRA, F-69621 Villeurbanne, France
[2] Hosp Civils Lyon, Hop E Herriot, Serv Nephrol Hypertens Hemodialyse, F-69003 Lyon, France
[3] Univ Claude Bernard Lyon 1, ENS Lyon, Prot Sci Facil, SFR BioSci,CNRS,UMS3444,Inserm,US8, F-69007 Lyon, France
关键词
HDL cholesterol; lipoproteins; cardiovascular risk; proteomic; mass spectrometry; hemodialysis; CARDIOVASCULAR EVENTS; HDL COMPOSITION; KIDNEY-DISEASE; MODALITIES; PROTEINS;
D O I
10.3390/toxins11110671
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Chronic kidney disease is associated with an increased cardiovascular risk, and altered biological properties of high-density lipoproteins (HDL) may play a role in these events. This study aimed to describe the HDL proteome from non-diabetic hemodialysis patients and identify potential pathways affected by the dysregulated expression of HDL proteins. HDL were sampled from nine non-diabetic hemodialysis (HD) and eight control patients. Samples were analyzed using a nano-RSLC coupled with a Q-Orbitrap. Data were processed by database searching using SequestHT against a human Swissprot database and quantified with a label-free quantification approach. Proteins that were in at least five of the eight control and six of the nine HD patients were analyzed. Analysis was based on pairwise ratios and the ANOVA hypothesis test. Among 522 potential proteins, 326 proteins were identified to be in the HDL proteome from HD and control patients, among which 10 were significantly upregulated and nine downregulated in HD patients compared to the control patients (p < 0.05). Up and downregulated proteins were involved in lipid metabolism, hemostasis, wound healing, oxidative stress, and apoptosis pathways. This difference in composition could partly explain HDL dysfunction in the chronic kidney disease (CKD) population and participate in the higher cardiovascular risk observed in this population.
引用
收藏
页数:10
相关论文
共 18 条
  • [1] Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
    Fellstroem, Bengt C.
    Jardine, Alan G.
    Schmieder, Roland E.
    Holdaas, Hallvard
    Bannister, Kym
    Beutler, Jaap
    Chae, Dong-Wan
    Chevaile, Alejandro
    Cobbe, Stuart M.
    Groenhagen-Riska, Carola
    De Lima, Jose J.
    Lins, Robert
    Mayer, Gert
    McMahon, Alan W.
    Parving, Hans-Henrik
    Remuzzi, Giuseppe
    Samuelsson, Ola
    Sonkodi, Sandor
    Sueleymanlar, Gultekin
    Tsakiris, Dimitrios
    Tesar, Vladimir
    Todorov, Vasil
    Wiecek, Andrzej
    Wuethrich, Rudolf P.
    Gottlow, Mattis
    Johnsson, Eva
    Zannad, Faiez
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) : 1395 - 1407
  • [2] Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins
    Florens, Nans
    Calzada, Catherine
    Lyasko, Egor
    Juillard, Laurent
    Soulage, Christophe O.
    [J]. TOXINS, 2016, 8 (12)
  • [3] Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease
    Gertow, Joanna
    Ng, Chang Zhi
    Branca, Rui Miguel Mamede
    Werngren, Olivera
    Du, Lei
    Kjellqvist, Sanela
    Hemmingsson, Peter
    Bruchfeld, Annette
    MacLaughlin, Helen
    Eriksson, Per
    Axelsson, Jonas
    Fisher, Rachel M.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2017, 2 (06): : 1208 - 1218
  • [4] Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    Go, AS
    Chertow, GM
    Fan, DJ
    McCulloch, CE
    Hsu, CY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) : 1296 - 1305
  • [5] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
    HAVEL, RJ
    EDER, HA
    BRAGDON, JH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) : 1345 - 1353
  • [6] The HDL proteome: a marker-and perhaps mediator-of coronary artery disease
    Heinecke, Jay W.
    [J]. JOURNAL OF LIPID RESEARCH, 2009, 50 : S167 - S171
  • [7] Dialysis Modalities and HDL Composition and Function
    Holzer, Michael
    Schilcher, Gernot
    Curcic, Sanja
    Trieb, Markus
    Ljubojevic, Senka
    Stojakovic, Tatjana
    Scharnagl, Hubert
    Kopecky, Chantal M.
    Rosenkranz, Alexander R.
    Heinemann, Akos
    Marsche, Gunther
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (09): : 2267 - 2276
  • [8] Uremia Alters HDL Composition and Function
    Holzer, Michael
    Birner-Gruenberger, Ruth
    Stojakovic, Tatjana
    El-Gamal, Dalia
    Binder, Veronika
    Wadsack, Christian
    Heinemann, Akos
    Marsche, Gunther
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (09): : 1631 - 1641
  • [9] HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach
    Mange, Alain
    Goux, Aurelie
    Badiou, Stephanie
    Patrier, Laure
    Canaud, Bernard
    Maudelonde, Thierry
    Cristol, Jean-Paul
    Solassol, Jerome
    [J]. PLOS ONE, 2012, 7 (03):
  • [10] HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
    Navab, Mohamad
    Reddy, Srinivasa T.
    Van Lenten, Brian J.
    Fogelman, Alan M.
    [J]. NATURE REVIEWS CARDIOLOGY, 2011, 8 (04) : 222 - 232